dc.creator | Fernández-Espejo, Emilio | es |
dc.creator | Gavito, Ana L. | es |
dc.creator | Suárez, Juan | es |
dc.creator | Tolosa, Eduardo | es |
dc.creator | Vilas, Dolores | es |
dc.creator | Aldecoa, Iban | es |
dc.creator | Berenguer, Juan | es |
dc.creator | Córdoba Fernández, Antonio | es |
dc.creator | Damas Hermoso, Fátima | es |
dc.creator | Rodríguez de Fonseca, Fernando | es |
dc.date.accessioned | 2023-06-28T12:54:55Z | |
dc.date.available | 2023-06-28T12:54:55Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Fernández Espejo, E., Gavito, A.L., Suárez, J., Tolosa, E., Vilas, D., Aldecoa, I.,...,Rodríguez de Fonseca, F. (2022). Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease. Clinical Parkinsonism & Related Disorders, 7, 100163. https://doi.org/10.1016/j.prdoa.2022.100163. | |
dc.identifier.issn | 2590-1125 | es |
dc.identifier.uri | https://hdl.handle.net/11441/147549 | |
dc.description.abstract | Background: ATP13A2 holds promise as biomarker for Parkinsońs disease (PD). No study has examined how
salivary ATP13A2 is related to motor features in idiopathic PD.
Methods: Salivary ATP13A2 concentration was evaluated with ELISA, and statistical correlations of ATP13A2
level with PD parameters were examined. The dose intensity of the dopaminergic medication regimen was
expressed as levodopa equivalent daily dose (LEDD). ATP13A2 expression on histological sections of subman dibular glands was evaluated using immunohistochemistry.
Results: Salivary ATP13A2 was undetectable in many subjects (28 % of patients, 43.7 % of controls). However, all
the patients with motor complications (n = 28) showed quantifiable levels of ATP13A2, that positively correlated
with MDS-UPDRS (total, parts III and IV), and LEDD (p < 0.05). Dyskinetic patients showed the highest LEDD
values (p < 0.05). The histological study revealed: a) ATP13A2 staining was very intense in duct cells and
vascular endothelium, and b) two patterns of ATP13A2-positive deposits are observed: rounded inclusions of
10–20 µm in diameter located in the interlobular tissue of the patients, and amorphous aggregates inside duct
lumen in controls and patients.
Conclusions: The sensitivity of the ELISA assay was a major limitation for quantifying ATP13A2. However,
salivary ATP13A2 was detected in all patients with motor complications, where a direct relationship among
ATP13A2 concentration, levodopa equivalent daily dose, and MDS-UPDRS was found. Therefore, salivary
ATP13A2 might be a reliable index of therapy-induced motor complications. ATP13A2 was expressed by rounded
inclusions in the submandibulary gland of patients. This is the first description of ATP13A2-positive inclusions
outside the nervous system. | es |
dc.format | application/pdf | es |
dc.format.extent | 7 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier BV | es |
dc.relation.ispartof | Clinical Parkinsonism & Related Disorders, 7, 100163. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | ATP13A2 | es |
dc.subject | Parkinsońs disease | es |
dc.subject | Saliva | es |
dc.subject | Levodopa equivalent dose | es |
dc.subject | Rounded inclusions | es |
dc.title | Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Podología | es |
dc.relation.projectID | PI19/01577 | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S2590112522000342?via%3Dihub | es |
dc.identifier.doi | 10.1016/j.prdoa.2022.100163 | es |
dc.contributor.group | Universidad de Sevilla. CTS589: Avances en Cirugía Podológica. | es |
dc.journaltitle | Clinical Parkinsonism & Related Disorders | es |
dc.publication.volumen | 7 | es |
dc.publication.initialPage | 100163 | es |
dc.contributor.funder | Unión Europea | es |
dc.contributor.funder | Junta de Andalucía | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |